UCB's Bimekizumab Shows Durable Remission, Hints at Retreatment Flexibility

Event summary

  • UCB presented data at the 2026 AAD Annual Meeting demonstrating 62.6% and 64.9% of patients achieved NPF-defined on-treatment remission with bimekizumab (BIMZELX) in the BE RADIANT and BE VIVID trials, respectively.
  • A post-hoc analysis showed 83.6% of patients achieved PASI 100 after retreatment with BIMZELX four years after stopping treatment.
  • The data utilizes a newly defined consensus definition of psoriasis on-treatment remission established by the National Psoriasis Foundation.
  • The findings suggest potential for re-establishing disease control with BIMZELX without significantly impacting long-term outcomes.

The big picture

UCB's BIMZELX is positioned as a key player in the psoriasis treatment landscape, competing with established biologics like ustekinumab and secukinumab. The data presented highlight the drug's potential for durable remission and retreatment efficacy, which could be a significant differentiator. The adoption of the NPF's new definition signals a shift towards more stringent benchmarks for treatment success in psoriasis, potentially impacting market share and pricing dynamics.

What we're watching

Adoption Rate
The uptake of the NPF's new remission definition by clinicians will influence how BIMZELX's efficacy is perceived and compared to competitors.
Commercial Impact
The demonstrated retreatment success could expand BIMZELX's market reach beyond initial treatment, potentially increasing lifetime patient value.
Regulatory Scrutiny
The post-hoc nature of these analyses may draw increased scrutiny from regulatory bodies regarding the robustness of long-term efficacy claims.